We are live on ! Find out more
OKYO

OKYO Pharma
OKYO

5 hedge funds and large institutions have $1.48M invested in OKYO Pharma in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.07% more ownership

Funds ownership: 6.12% → 8.19% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

29% less funds holding

Funds holding: 7 → 5 (-2)

44% less capital invested

Capital invested by funds: $2.63M → $1.48M (-$1.16M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DIG
Dauntless Investment Group
New Hampshire
+$1.27M
2
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services
Minnesota
+$16.9K
3
UBS Group
UBS Group
Switzerland
+$195

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$34.8K
2
FIA
FNY Investment Advisers
New York
-$25K
3
Renaissance Technologies
Renaissance Technologies
New York
-$17.7K
4
CA
Continuum Advisory
Idaho
-$64

OKYO Hedge Fund Activity: Q2 2025 in Review

5 of the 7,615 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2025, worth a combined $1.48M — down 44% from $2.63M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of OKYO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Dauntless Investment Group, adding an estimated $1.27M. The largest seller was Citadel Advisors, exiting entirely with an estimated $34.8K sold.

  • 5 institutional investors held OKYO Pharma (OKYO) as of Q2 2025, down from 7 in Q1 2025.
  • Funds reported $1.48M of OKYO Pharma stock for Q2 2025, down 44% quarter-over-quarter.
  • 2 funds opened new OKYO Pharma positions in Q2 2025 and 4 closed out, a net change of -2 holders.
  • The largest OKYO Pharma buyer in Q2 2025 was Dauntless Investment Group, an estimated $1.27M added.
  • The largest OKYO Pharma seller in Q2 2025 was Citadel Advisors, an estimated $34.8K sold.

Based on aggregated 13F filings for Q2 2025.